MyelinWatch EL
← Back to updates
Emerging treatmentsMyelin repair
Results from peopleTerminated / stoppedStudy stopped before a clear answer about whether it helps

Phase 3

RESTORE: the Phase 3 clemastine study stopped after an early review found it was unlikely to reach its goal

Worth knowing

RESTORE tested clemastine in people with MS and a disorder affecting eye movement. It was stopped after slow enrolment led to an early review, which found that the study was unlikely to reach its goal.

What this means for people with MS

This is an important negative development for this study. It should not be treated as a clear result about whether clemastine works, because the decision was made in a study that had serious difficulty finding participants.

What kind of evidence exists?
ClinicalTrials.gov • update on the study's status
How reliable is this source?
High • ClinicalTrials.gov registry status

Related study or programme: RESTORE →

ClinicalTrials.govRead the source ↗

Related substantive developments

Myelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding

Laboratory and animal research

Blocking fibronectin restored remyelination in experimental models

A PNAS study found that a protein called fibronectin can build up in areas where myelin has been lost. This may trap immature cells that could otherwise become myelin-making cells. Blocking fibronectin improved myelin repair and symptoms in two animal models.

Read the update →Peer-reviewed paper
Emerging treatmentsMyelin repair
Registered study in peopleOngoing, but not accepting participantsNo evidence of benefit in people yet

Phase 3 study that can add or remove treatments

OCTOPUS: the first review of metformin and alpha-lipoic acid is planned for September 2026

The first OCTOPUS review in progressive MS will assess metformin and alpha-lipoic acid. It will look at brain shrinkage on MRI, disability, walking speed and hand function.

Read the update →University / investigator